GlassScriptPhysician profile
Richard M Contro
NPI 1578737920
$7,597.87
in general payments reported to CMS, 2019-2025
35 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $678 · 2021: $1,211 · 2022: $970 · 2023: $1,418 · 2024: $1,275 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,683.16 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Bausch Health US, LLC | $1,338.98 | 2020-2025 | Aplenzin |
| Astellas Pharma US INC | $819.69 | 2020-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $516.68 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $348.48 | 2020-2021 | |
| Therapeuticsmd, INC. | $324.87 | 2019-2022 | |
| Amgen INC. | $288.01 | 2019-2025 | Evenity, Prolia, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $277.95 | 2020-2025 | Trintellix |
| Pfizer INC. | $180.42 | 2021-2025 | |
| Lilly USA, LLC | $163.28 | 2019-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $139.63 | 2022 | |
| Terumo Medical Corporation | $137.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $134.40 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $117.74 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $115.60 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $115.09 | 2019-2021 | |
| Alfasigma USA, INC. | $114.49 | 2020-2022 | |
| Myovant Sciences INC. | $108.01 | 2021-2022 | |
| Avion Pharmaceuticals | $90.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $84.58 | 2021-2023 | Belsomra |
| Eisai INC. | $60.29 | 2020-2022 | |
| Exact Sciences Corporation | $49.53 | 2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $49.42 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $45.11 | 2023-2025 | Myfembree |
| Lundbeck LLC | $40.31 | 2024 | Rexulti |
| Ethicon US, LLC | $38.28 | 2022 | |
| Novo Nordisk INC | $36.09 | 2023-2024 | Wegovy |
| Baxter Healthcare | $35.29 | 2025 | Perclot |
| Hologic Sales and Service, LLC | $22.69 | 2019 | |
| Meditrina | $22.22 | 2024 | |
| Allergan, INC. | $21.05 | 2020 | |
| Becton, Dickinson and Company | $20.85 | 2020 | |
| Lupin INC. | $20.78 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.72 | 2023 | Quviviq |
| Coopersurgical, INC. | $17.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Contro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.